David Charles, B.S. ; Kate D. Schoyer, M.Da

Slides:



Advertisements
Similar presentations
ART-IVF: the Long and Short of it Professor Ernest Hung Yu NG Department of Obstetrics & Gynaecology The University of Hong Kong.
Advertisements

Minimal Monitoring of Ovulation Induction (OI) Is It Safe? Mustafa Uğur Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, Turkey.
Breast Cancer, Fertility and Pregnancy
Role of Anti-Mullerian hormone in prediction of Assisted Reproductive Technology outcomes Leili Safdarian M.D. Khadigeh Khosravi M.D. Marzieh Agha Hosseini.
Discontinuation of rLH two days before hCG may increase the number of oocytes retrieved in IVF Jessica B Spencer 1*, Aimee S Browne 1, Susannah D Copland.
In candidates for assisted conception serum FSH but not oestradiol is related to declining ovarian reserve in the fourth decade AP Brown 1, L Maddison.
TEMPLATE DESIGN © Oocyte donation outcomes at Alpha International Fertility Centre IntroductionResultsConclusions References.
The Effect of Bromocriptine-Rebound Method on Ongoing Pregnancy and Live Birth after Intracytoplasmic Sperm Injection Cycles: a Randomized Clinical Trial.
The 4th Misurata scientific meeting of infertility Benghazi – Libya 10/10/2008 Dr. Omar A. Elsraiti Consultant of Obst. & Gyn. IVF Centre - Misurata /
Agonist vs Antagonist Dr. Milton Leong.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Facilitator: Pawin Puapornpong
Value of the chemiluminescence Elecsys antimullerian hormone assay for the assessment of the ovarian follicle pool: preliminary study at the IASO- IVF.
The Importance Of Determination Of Ovulation In Women Undergoing Ovulation Induction Şebnem ALANYA TOSUN, MD Assistant Professor of Obstetrics and Gynecology.
Duration of symptoms (years)
UOG Journal Club: October 2016
Purposeful rotation of outer guide catheter just prior to embryo transfer: Does it enhance the pregnancy rate in women undergoing assisted reproduction.
Isfahan University of Medical Sciences Dissertation defense meeting Resident of Gynecology and Obstetrics.
Oocyte retrieval at 140 mm Hg negative aspiration pressure – a promising alternative to flushing and aspiration in Assisted Reproduction Dr.Aswathy Kumaran**
Mohamed Elmahdy MD. Lecturer Obs. Gyn. Alexandria University Egypt
Obesity and its metabolic complications in IVF
Özkan Özdamar, M.D., Assist. Prof.
To operate or not to operate before IVF
The long-term effect of endometrioma surgery on ovarian reserve:
Pregnancy outcomes after assisted reproductive procedures of embryos derived from affected and unaffected ovaries among women with small unilateral endometriomas.
Reproduction-Related Disorders
Aging and Infertility. Part 2. National Infertility Centre
Introduction Ovarian reserve is injured following surgical excision of ovarian endometriomas Garcia-Velasco JA, Somigliana E., Hum Reprod, 2009 Bilateral.
The effect of the duration of stimulation on ART outcomes
Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.
Patient-specific predictions of outcome after gonadotropin ovulation induction/intrauterine insemination  Randi H. Goldman, M.D., Maria Batsis, M.D.,
Nicole Banks, M. D. , George Patounakis, M. D. , Ph. D
Norbert Gleicher, Andrea Weghofer, David H. Barad 
Age at menarche: a predictor of diminished ovarian function?
Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction  Antonio La Marca, Giovanni D’Ippolito 
The predictive value for in vitro fertility delivery rates is greatly impacted by the method used to select the threshold between normal and elevated.
James P Toner, M.D., Ph.D.  Fertility and Sterility 
Patient-tailored ovarian stimulation for in vitro fertilization
What is the optimal follicular size before triggering ovulation in intrauterine insemination cycles with clomiphene citrate or letrozole? An analysis.
THE SPERM ACROSOME REACTION RESPONSE TO PROGESTERONE ASSOCIATED WITH SPERM DNA DAMAGE HAS A BETTER PREDICTING VALUE FOR IVF THAN THAT RESPONSE TO THE IONOPHORE.
Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for.
Orhan Bukulmez, M. D. , Qin Li, M. S. , Bruce R. Carr, M. D
Genotypically determined ancestry across an infertile population: ovarian reserve and response parameters are not influenced by continental origin  Meir.
Biomarkers of ovarian response: current and future applications
Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D. 
Utility of age-specific serum anti-Müllerian hormone concentrations
Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response  Frank.
There is significant unexplained inter-cycle variation in ovarian performance during IVF treatment Thanos Papathanasiou, Nausheen Mawal, Phil Snell. Bourn.
Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis  Cui Hong Zheng, M.D., Ph.D.,
How to do a study? Prof. P. Devroey.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D. 
Dr. Kenneth Egwuda MBBS, PGA-ART(Lon), ESGE(Belg.),FMAS,FWACS,FMCOG
Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.
Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating.
Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in.
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.
Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.
Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists 
Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function  David H. Barad, M.D., M.S., Andrea Weghofer,
Urinary paraben concentrations and in vitro fertilization outcomes among women from a fertility clinic  Lidia Mínguez-Alarcón, Ph.D., Yu-Han Chiu, M.D.,
Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve  Norbert.
Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle- stimulating hormone (FSH) in normoandrogenic ovulatory women.
Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles2 
A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three- dimensional ultrasound determinants of ovarian reserve in the prediction.
Male age negatively impacts embryo development and reproductive outcome in donor oocyte assisted reproductive technology cycles  John L. Frattarelli,
Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated.
Presentation transcript:

David Charles, B.S. ; Kate D. Schoyer, M.Da Establishing an Evidence Based Cutoff: Basal Follicle Stimulating Hormone (FSH) Levels of 8 or Greater to Detect Diminished Ovarian Reserve in Young Women Paige Persch, M.D.a ; Alexis Visotcky, M.S.b ; Aniko Szabo, PhD b; Estil Strawn, M.D.a , Theresa Piquette, M.D. a; David Charles, B.S. ; Kate D. Schoyer, M.Da aDepartment of Obstetrics and Gynecology and the bDepartment of Biostatistics Findings still significant when logistic regression analysis performed, controlling for age, day 3 estradiol level, day of transfer (3 versus 5), number of embryos transferred, ovulation trigger (Lupron plus hCG versus hCG) and type of transfer (fresh versus frozen.) A receiver operator characteristic curve was also created using FSH levels as a predictor for clinical pregnancy rates (not shown.) The area under the curve was 0.55. The highest combination of sensitivity and specificity were seen at an FSH of 6.70 at 64% and 47%, respectively. INTRODUCTION RESULTS -Assessment of ovarian reserve with cycle day 2 or 3 FSH and estradiol is one of the critical steps in evaluation of couples seeking treatment for infertility (1). -Traditionally, an FSH greater than 10 mIU/mL is the level at which diminished ovarian reserve is diagnosed (1). -Prior studies have shown those with “premature ovarian aging” to have FSH levels less than 10 mIU/mL but who are in either greater than the 95% confidence interval (5,6), or in the highest quartile in their age groups (7). -Young women in the premature ovarian aging groups had decreased number of oocytes retrieved after ovarian stimulation for in vitro fertilization (IVF) compared to their counterparts despite technically normal FSH levels. -As FSH level is a widely used marker to guide treatment, it would be valuable to obtain further data regarding pregnancy outcomes in the younger age group of women undergoing IVF to see if a new cut-off level should instead be used. <8 N=298 >=8 to <=10 N=54 P Value Age 30.9 +/- 2.4 31.1 +/- 2.3 0.58 BMI 27.2 +/- 6.0 25.5 +/- 5.4 0.06 Ethnicity 0.66 Asian 17 (5.7 %) 1 (1.9 %) Hispanic 16 (5.4 %) 3 (5.6 %) Indian 5 (1.7 %) 0 (0.0 %) Non- black 8 (2.7 %) 1 (1.9 %) White 257 (84.6 %) 49 (90.7 %) DISCUSSION Our findings suggest that an FSH level of 8 or greater may be predictive of poorer outcomes with IVF in young women, specifically, with lower clinical pregnancy rates seen in the FSH 8-10 group versus FSH <8. This finding was still significant when controlling for confounding variables via logistic regression analysis. This suggests that in young women, using a cutoff of 8 rather than 10 may identify those who may benefit from more aggressive fertility treatment. Strengths: -Powered for primary outcome -High number of single embryo transfers -Homogenous stimulation protocols Weaknesses: -FSH has some inherent variability and is limited as a screening test -Retrospective study . Table 1. Demographic data <8 N=298 >=8 to <=10 N=54 P Value Day 3 Estradiol (pg/mL) 37.6 +/- 16.0 40.3 +/- 14.5 0.248 Antral follicle count 17.6 +/- 10.1 13.8 +/- 7.3 0.008 AMH level (ng/mL) 4.7 +/- 4.7 3.0 +/- 3.1 0.010 OBJECTIVES Figure 1. Subject numbers after screening for exclusion criteria The aim of this study was to assess whether high-normal basal FSH levels between 8-10 lead to significantly different outcomes for women ages 35 or younger undergoing in vitro fertilization, compared to women with FSH levels less than 8. The primary outcome was clinical pregnancy rates, defined by the presence of fetal heartbeat(s) on ultrasound. Table 2. Markers of ovarian reserve <8 N=298 >=8 to <=10 N=54 P Value Days of stimulation 10.0 +/- 1.7 10.2 +/- 1.5 0.37 Ampules of gonadotropins 33.0 +/- 16.4 36.9 +/- 13.1 0.10 Total oocytes retrieved 13.7 +/- 7.2 12.6 +/- 6.9 0.31 Mature Oocytes 10.5 +/- 5.9 9.8 +/- 5.9 0.41 Total number of embryos 7.9 +/- 5.0 7.3 +/- 5.1 0.44 REFERENCES METHODS 1. The Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril 2015;103(3):e9-e17. 2. Levi AJ, Raynault MF, Bergh PA, Drews MR, Miller BT, Scott RT Jr. Reproductive outcome in patients with diminished ovarian reserve. Fertil Steril 2001;76:666-9. 3. Navot D, Rosenwaks Z, Margalioth EJ. Prognostic assessment of female fecundity. Lancet 1987;2:645-7 4. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 1989;51:651-4 5. Barad DH, Weghofer A, Gleicher N. Age-specific levels for basal follicle-stimulating hormone assessment of ovarian function. Obstet Gynecol. 2007;109:1404-10. 6. Fang T, Su Z, Wang L, Yuan P, Li R, Ouyang N, Zheng L, Wang W. Predictive value of age-specific FSH levels for IVF-ET outcome in women with normal ovarian function. Repro Bio and Endo. 2015;13:63. 7. Weghofer A, Mergreiter M, Fauster Y, Schaetz T, Brandstetter A, Boehm D, et al. Age-specific FSH levels as a tool for appropriate patient counselling in assisted reproduction. Hum Reprod. 2005;20:2448-52. 8. Kumbak B, Oral E, Kahraman S, Karlikaya G, Karagozoglu H. Young patients with diminished ovarian reserve undergoing assisted reproductive treatments: a preliminary report. Repro BioMed Online. 2005;11(3):294-299. -Chart review of all women age 35 or younger who underwent their first IVF attempt between 1/1/2010 and 12/19/2016, all of whom had a day 2/3 FSH and estradiol drawn within one year of their IVF cycle. -Powered to detect a 20% lower probability of clinical pregnancy in patients with FSH between 8 and 10 compared to FSH under 8 at a one-sided 5% significance level based on prior data (8). -For the primary analysis, the focus was on comparing patients with FSH under 8 and those with FSH 8 – 10. The probability of clinical pregnancy was compared between the two groups using Pearson’s chi-squared test at a 5% significance level. The difference in the proportion of patients with clinical pregnancy was estimated, and reported with a 95% confidence interval. Table 3. Ovarian stimulation outcomes <8 N=298 >=8 to <=10 N=54 P Value Positive bHCG 174 (59.8%) 29 (54.7%) 0.49 Clinical pregnancy 127 (43.8%) 15 (28.3%) 0.035 Table 4. Pregnancy outcomes ACKNOWLEDGEMENT Figure 2. Clinical pregnancy rate by FSH level Thank you to the resident research committee in the Department of Obstetrics and Gynecology at the Medical College of Wisconsin Affiliated Hospitals